Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

Inclusion Criteria: * Male or female patients 2 to 11 years of age. * Parent or LAR provides signed informed consent and patient provides assent (when applicable). * Confirmed diagnosis of HAE. Exclusion Criteria: * Confirmed diagnosis of HAE with nC1-INH or acquired angioedema * Patient weighs \<9.5 kg * Patient participated in the KVD900-303 trial and withdrew prior to trial completion per the protocol or trial closure * Any clinically significant medical condition or medical history that, in the opinion of the Treating Physician, would interfere with the patient's safety. * Known hypersensitivity to sebetralstat or its excipients. * Patient with a medical history or known to have severe hepatic impairment (Child Pugh C). * Patients who require sustained use of strong cytochrome P450 3A4 inhibitors or inducers.